Viking Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year Four
Viking Therapeutics, Inc. (VKTX) had Lessee, Operating Lease, Liability, to be Paid, Year Four of $29.00 thousand as of 2019-09-30, per its 10-Q filed 2019-11-05.
Discontinued › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour · last filed 2019-11-05
- 2019-09-30: Lessee, Operating Lease, Liability, to be Paid, Year Four $29.00K.
- 2019-06-30: Lessee, Operating Lease, Liability, to be Paid, Year Four $29.00K.
- 2019-03-31: Lessee, Operating Lease, Liability, to be Paid, Year Four $29.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year Four |
|---|---|
| 2019-09-30 | $29.00K 10-Q · filed 2019-11-05 |
| 2019-06-30 | $29.00K 10-Q · filed 2019-08-01 |
| 2019-03-31 | $29.00K 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |